Patient-specific stem cells have been heralded as the next frontier in regenerative medicine. Although most therapies are probably a decade or more away, for one life-threatening skin disease the first clinical trials involving induced pluripotent stem cells may begin as early as 2014. Monya Baker investigates.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baker, M. Reprogramming Rx. Nat Med 17, 241–243 (2011). https://doi.org/10.1038/nm0311-241
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0311-241
- Springer Nature America, Inc.